Glenmark Pharmaceuticals launches Type 2 diabetes drug Zita D in India

Glenmark Pharmaceuticals has launched Zita D the brand name for Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination in India for the treatment of Type 2 diabetes in adult patients, especially those with comorbidities.

According to Glenmark Pharmaceuticals, Zita D has to be taken daily once by Type 2 diabetic patients under prescription for enhancing glycemic control and the prevention of complications.

Alok Malik — Glenmark Pharmaceuticals EVP & Business Head of India Formulations said: “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities.

See also  AbbVie's SKYRIZI wins FDA approval for ulcerative colitis treatment

“Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.”

Teneligliptin is a broadly used inhibitor of dipeptidyl peptidase 4 (DPP4), while Dapagliflozin is a commonly prescribed Sodium glucose co‐transporter 2 (SGLT‐2i) inhibitor for patients with diabetes in India.

See also  Panacea Biotec gets $127.3m worth orders for Easyfive-TT from UNICEF, PAHO

Glenmark Pharmaceuticals said that Zita D costs around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for the fixed dose combination of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.